Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
Nagahide Takahashi,1 Maayoshi Takahashi,2 Takayuki Saito,3 Misuzu Iizumi,4 Yuki Saito,5 Hiroko Shimizu,6 Taka Matsumura7 1Clinical Responsible Physicians Department, Clinical Science Division, 2Clinical Science Initiative Department, Clinical Science Division, 3Project Lead Department, Project Devel...
Enregistré dans:
Auteurs principaux: | Takahashi N, Takahashi M, Saito T, Iizumi M, Saito Y, Shimizu H, Matsumura T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c2c8f18db661450a959b5d0d8d7a759d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017) -
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015) -
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017) -
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016) -
Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)